Bmp modulators in kidney disease.

Career-Path Promotion Unit for Young Life Scientists, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Discovery medicine (Impact Factor: 3.5). 01/2012; 13(68):57-63.
Source: PubMed

ABSTRACT Bone morphogenetic proteins (Bmps) are phylogenetically conserved signaling molecules that belong to the transforming growth factor beta superfamily. Although these proteins were first identified because of their ability to induce ectopic bone and cartilage formation, they are also involved in the cascades of body patterning and morphogenesis. Recently, several reports have indicated that the administration of pharmacological doses of Bmps inhibits and repairs acute and chronic renal injury in animal models. However, its mechanism of action and physiological function are not well understood. In addition, the exogenous administration of Bmps causes undesired side effects in other tissues, because Bmp receptors are widely expressed. The activities of Bmps are regulated by Bmp antagonists, which bind directly to Bmp and inhibit its binding to the receptor. Thus, the Bmp antagonists that modulate endogenous Bmp activities may be possible new therapeutic targets for kidney disease. In this review, we discuss recent findings related to Bmp antagonists modifying the function of Bmps in kidney disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: TGF-β (transforming growth factor-β) and BMP-7 (bone morphogenetic protein-7), two key members in the TGF-β superfamily, play important but diverse roles in CKDs (chronic kidney diseases). Both TGF-β and BMP-7 share similar downstream Smad signalling pathways, but counter-regulate each other to maintain the balance of their biological activities. During renal injury in CKDs, this balance is significantly altered because TGF-β signalling is up-regulated by inducing TGF-β1 and activating Smad3, whereas BMP-7 and its downstream Smad1/5/8 are down-regulated. In the context of renal fibrosis, Smad3 is pathogenic, whereas Smad2 and Smad7 are renoprotective. However, this counter-balancing mechanism is also altered because TGF-β1 induces Smurf2, a ubiquitin E3-ligase, to target Smad7 as well as Smad2 for degradation. Thus overexpression of renal Smad7 restores the balance of TGF-β/Smad signalling and has therapeutic effect on CKDs. Recent studies also found that Smad3 mediated renal fibrosis by up-regulating miR-21 (where miR represents microRNA) and miR-192, but down-regulating miR-29 and miR-200 families. Therefore restoring miR-29/miR-200 or suppressing miR-21/miR-192 is able to treat progressive renal fibrosis. Furthermore, activation of TGF-β/Smad signalling inhibits renal BMP-7 expression and BMP/Smad signalling. On the other hand, overexpression of renal BMP-7 is capable of inhibiting TGF-β/Smad3 signalling and protects the kidney from TGF-β-mediated renal injury. This counter-regulation not only expands our understanding of the causes of renal injury, but also suggests the therapeutic potential by targeting TGF-β/Smad signalling or restoring BMP-7 in CKDs. Taken together, the current understanding of the distinct roles and mechanisms of TGF-β and BMP-7 in CKDs implies that targeting the TGF-β/Smad pathway or restoring BMP-7 signalling may represent novel and effective therapies for CKDs.
    Clinical Science 02/2013; 124(4):243-54. · 5.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily of secreted cysteine knot proteins which includes TGF-β1, nodal, activins and inhibins. BMPs were first discovered by Urist in the 1960s when he showed that implantation of demineralised bone into intramuscular tissue of rabbits induced bone and cartilage formation. Since this seminal discovery, BMPs have also been shown to play key roles in several other biological processes including limb, kidney, skin, hair and neuronal development as well maintaining vascular homeostasis. The multifunctional effects of BMPs make them attractive targets for the treatment for several pathologies including bone disorders, kidney and lung fibrosis and cancer. This review will summarise current knowledge on the BMP signalling pathway and critically evaluate the potential of recombinant BMP as pharmacological agents for the treatment bone repair and tissue fibrosis in patients.
    British Journal of Pharmacology 04/2014; · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone Morphogenetic Protein-2 (BMP-2) has displayed a crucial role in the development of cardiogenesis recently, and can be used in the induction of bone marrow mesenchymal stem cells (BMMSCs) differentiation into cardiomyocytes. In this study, we examined the differentiation effects of rat BMMSCs into cardiomyocyte-like cells by inducing with combination of BMP-2 and 5-azacytidine (5-AZA). BMMSCs were collected and purified from bone marrow of 4-week-old Sprague-Dawley (SD) rats by using density-gradient centrifugation and differential attachment method. The forth passage subculture of BMMSCs were detected by cytometry analysis for purity identification, and were divided into four groups: Control group, BMP-2 group, 5-AZA group, the combination of BMP-2 and 5-AZA group. The expressions of cardiac Troponin I (cTnI) and Connexin 43 (CX-43) in BMMSCs after induction were detected by immunofluorescence and Western Blot. Flow cytometry analysis was performed for differentiation rates and the apoptosis of induced BMMSCs, by detecting the expressions of cardiac Troponin T (cTnT) and using Annexin V-FITC & PI kit, respectively. Our results demonstrated that BMP-2 have ameliorated the apoptosis of BMMSCs caused by 5-AZA and promoted the differentiation of BMMSCs into cardiomyocyte-like cells. In conclusion, the combination of BMP-2 and 5-AZA can significantly improve the cardiac differentiation rate and exhibit lower cell damage effects, which could be a safe and effective method of induction in vitro.
    Cell Biology International 07/2013; · 1.64 Impact Factor